Actelion Ltd. climbed the most in more than five months after the Swiss maker of the Tracleer lung drug reiterated its profit forecast for 2013.
Actelion rose 3.4 percent to 46.26 Swiss francs in Zurich, the biggest advance since July 19. The volume of shares traded was more than double the three-month daily average.
Earnings in 2013 will about match figures from last year, with “single-digit percentage growth” in 2014 and a double-digit increase in 2015 because of sales of macitentan, a planned successor to Tracleer, the Allschwil-based company said in a presentation posted on its website after the close of trading yesterday.
“Full year 2012 was an exciting year, laying the stepping stone for further success by demonstrating that macitentan is a very good and efficacious drug,” Andrew Weiss, an analyst at Bank Vontobel AB, wrote in a note today. “Earnings guidance for 2013 is confirmed.”